vTv Therapeutics Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $36.8M | $0 | $0 | $0 | $0 | $17.0K | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $8.8M | $9.0M | $3.9M | $7.0M | $4.1M | $2.8M | $2.2M | $3.2M |
| SG&A Expense | $5.2M | $4.6M | $4.0M | $3.7M | $3.6M | $3.7M | $2.7M | $3.3M |
| Operating Income | $-13.9M | $23.3M | $-7.9M | $-10.7M | $-7.7M | $-6.5M | $-4.9M | $-6.5M |
| Operating Margin | — | 63.1% | — | — | — | — | -28,776.5% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-13.1M | $24.1M | $-7.1M | $-10.3M | $-7.4M | $-6.2M | $-4.4M | $-5.8M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-13.1M | $24.1M | $-7.1M | $-8.7M | $-6.0M | $-5.1M | $-3.6M | $-4.8M |
| Net Margin | — | 65.5% | — | — | — | — | -21,376.5% | — |
| EPS (Basic) | — | — | — | — | — | — | — | — |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Diluted) | — | — | — | — | — | — | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |